Mayne Pharma slumps 30% as Cosette threatens to scrap $432 million deal

  • Shares of Mayne Pharma plunged 30% on Wednesday after U.S.-based Cosette Pharmaceuticals initiated a review of its A$672 million ($432.1 million) acquisition, citing a "material adverse change" in the Australian firm's business and finances.